- Home
- BMEZ vs ARQT Comparison
BMEZ vs ARQT Comparison
Compare BMEZ & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMEZ | ARQT |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 953.1M | 3.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BMEZ | ARQT |
|---|---|---|
| Price | $15.12 | $28.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.83 |
| AVG Volume (30 Days) | 391.3K | ★ 2.3M |
| Earning Date | 01-01-0001 | 10-28-2025 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | N/A | ★ $317,929,000.00 |
| Revenue This Year | N/A | $85.51 |
| Revenue Next Year | N/A | $30.74 |
| P/E Ratio | $30.17 | ★ N/A |
| Revenue Growth | N/A | ★ 129.21 |
| 52 Week Low | $12.93 | $11.13 |
| 52 Week High | $16.95 | $31.77 |
Technical Indicators
Market Signals| Indicator | BMEZ | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 50.68 | 54.70 |
| Support Level | $15.10 | $29.30 |
| Resistance Level | $15.38 | $31.77 |
| Average True Range (ATR) | 0.24 | 1.13 |
| MACD | -0.02 | -0.40 |
| Stochastic Oscillator | 35.50 | 15.99 |
Price Performance
Historical ComparisonAbout BMEZ BlackRock Health Sciences Term Trust of Beneficial Interest
BlackRock Health Sciences Trust II is a closed-ended management investment company. The investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.